1 BTC
=
- USD
Curis Inc
As of May 30, 2026 at 24:05 UTC
Chart
About Curis Inc
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
Market Statistics
Trading Metrics
How to Buy CRIS
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy CRIS
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesCuris reported Q4 2025 net income of $19.4 million ($1.23 per share) driven by a $27.2 million one-time gain from selling Erivedge to Oberland. The company has eliminated legacy revenue streams and is now focused on advancing its TakeAim Lymphoma (PCNSL) registrational study and initiating a CLL proof-of-concept study. With $20.2 million in PIPE financing received in January 2026 and potential additional $20.2 million upon CLL milestone achievement, the company expects to fund operations into 2027. Early AML triplet therapy data showed five of eight evaluable patients achieved MRD conversion.
Biotechnology company Curis reported a narrowed Q2 2025 net loss of $0.68 per share, beating analyst expectations. The company continues advancing its cancer therapy emavusertib while facing near-term funding challenges, with cash reserves expected to last only into Q1 2026.
VISTA inhibitors are an emerging class of immunotherapeutic agents with significant potential in treating cancer and autoimmune diseases. Several companies are actively pursuing VISTA inhibitors, which offer a novel mechanism of action and broad applicability, but also face challenges such as complex development landscape and competition from existing therapies.
As of April 12, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above ...
